What is 3Derm?
3Derm operates at the intersection of medical imaging and artificial intelligence, providing a sophisticated platform designed to elevate the standard of dermatological care. The company's core value proposition lies in its proprietary imaging system, which facilitates high-fidelity data capture essential for accurate clinical assessment. Beyond hardware, 3Derm has distinguished itself through the development of world-class diagnostic algorithms, which have earned FDA Breakthrough Device designations for their efficacy in autonomous skin cancer detection.
By integrating these tools into teledermatology workflows, 3Derm enables healthcare providers to optimize patient triage and improve diagnostic precision. The company serves a diverse array of healthcare organizations, offering a scalable solution that addresses the growing demand for remote, technology-driven dermatological services. Its focus on clinical accuracy and operational efficiency positions it as a pivotal player in the modernization of skin health diagnostics.
How much funding has 3Derm raised?
3Derm has raised a total of $2.8M across 2 funding rounds:
Private Equity
$1.2M
Private Equity
$1.7M
Private Equity (2014): $1.2M, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
Key Investors in 3Derm
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for 3Derm?
With the recent influx of capital, 3Derm is poised to transition into a phase of aggressive market expansion and product refinement. The strategic focus will likely center on the commercialization of its FDA-cleared AI diagnostic tools, aiming to integrate these solutions into broader clinical networks and hospital systems. As the company scales, the emphasis will remain on maintaining the integrity of its diagnostic algorithms while expanding its footprint in the teledermatology market.
Future growth will be driven by the continued adoption of its autonomous screening technology, which promises to reduce the burden on specialists and improve patient outcomes through early detection. By capitalizing on its current momentum, 3Derm is well-positioned to define the next generation of digital dermatology, setting new benchmarks for how skin disease is identified and managed in a clinical setting.
